Ceragenix Achieves 200 Days Of Antimicrobial Efficacy On Treated Silicone Medical Device

Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP) (the “Company”), a medical device company focused on infectious disease and dermatology, announced that preclinical testing of a silicone medical device incorporating the Company’s CeraShield? antimicrobial technology has achieved 200 days of continuous antimicrobial efficacy. The prototype device being tested is an intravaginal silicone ring.

More: continued here

Filed under: Dermatology on May 6th, 2009